Anne Niquille1, Olivier Bugnon. 1. School of pharmaceutical sciences, University of Geneva, University of Lausanne, Community Pharmacy, Pharmacie de la PMU, 44 Rue du Bugnon, 1011 Lausanne, Switzerland. anne.niquille@hospvd.ch
Abstract
OBJECTIVE: To describe drug-related problems (DRPs) and expense problems (EPs) identified by a standardised community pharmacist-based medication review (MR) program among Swiss cardiovascular outpatients (56-75 years old) and to evaluate the need for collaborative pharmacy practice to achieve economic, clinical and humanistic outcomes. SETTING: A pilot population of 85 cardiovascular outpatients who were customers of 14 community pharmacies (members of the pharmacieplus virtual chain) and insured with Groupe Mutuel health insurance. METHOD: Cross-sectional study of a structured medication review program, conducted by 11 pharmacists in collaboration with 61 general practitioners (GPs), with patient interviews and access to medical data. MAIN OUTCOME MEASURE: Numbers and types of DRPs and EPs within the study population and odds ratios between them, as well as economic, clinical and humanistic outcomes. RESULTS: Of the included patients, 91% had at least one DRP or EP. The odds ratios indicated that not being exposed to DRPs was associated with a higher chance of reaching the clinical target (OR: 3.4; IC95%:1.1-10.5; P = 0.01), of having a better physical quality of life than the median (OR: 2.5; IC95%: 0.9-7.3; P = 0.05) and having lower total health care costs (OR: 3.2; IC95%:1.1-9.8; P = 0.02). CONCLUSIONS: This cross-sectional study shows that the control of cardiovascular risk factors, quality of life and healthcare costs are statistically related to the presence of DRPs detected by a community pharmacist-based MR program.
OBJECTIVE: To describe drug-related problems (DRPs) and expense problems (EPs) identified by a standardised community pharmacist-based medication review (MR) program among Swiss cardiovascular outpatients (56-75 years old) and to evaluate the need for collaborative pharmacy practice to achieve economic, clinical and humanistic outcomes. SETTING: A pilot population of 85 cardiovascular outpatients who were customers of 14 community pharmacies (members of the pharmacieplus virtual chain) and insured with Groupe Mutuel health insurance. METHOD: Cross-sectional study of a structured medication review program, conducted by 11 pharmacists in collaboration with 61 general practitioners (GPs), with patient interviews and access to medical data. MAIN OUTCOME MEASURE: Numbers and types of DRPs and EPs within the study population and odds ratios between them, as well as economic, clinical and humanistic outcomes. RESULTS: Of the included patients, 91% had at least one DRP or EP. The odds ratios indicated that not being exposed to DRPs was associated with a higher chance of reaching the clinical target (OR: 3.4; IC95%:1.1-10.5; P = 0.01), of having a better physical quality of life than the median (OR: 2.5; IC95%: 0.9-7.3; P = 0.05) and having lower total health care costs (OR: 3.2; IC95%:1.1-9.8; P = 0.02). CONCLUSIONS: This cross-sectional study shows that the control of cardiovascular risk factors, quality of life and healthcare costs are statistically related to the presence of DRPs detected by a community pharmacist-based MR program.
Authors: Nicolas Rodondi; Tiffany Peng; Andrew J Karter; Douglas C Bauer; Eric Vittinghoff; Simon Tang; Daniel Pettitt; Eve A Kerr; Joe V Selby Journal: Ann Intern Med Date: 2006-04-04 Impact factor: 25.391
Authors: Anneleen Robberechts; Céline De Petter; Lindsey Van Loon; Silas Rydant; Stephane Steurbaut; Guido De Meyer; Hans De Loof Journal: Int J Clin Pharm Date: 2021-01-23
Authors: Floor Willeboordse; Jacqueline G Hugtenburg; François G Schellevis; Petra J M Elders Journal: Br J Clin Pharmacol Date: 2014-12 Impact factor: 4.335
Authors: Gilberto M Sperandio da Silva; Mayara C Chambela; Andrea S Sousa; Luiz Henrique C Sangenis; Sergio S Xavier; Andréa R Costa; Pedro Emmanuel A A Brasil; Alejandro M Hasslocher-Moreno; Roberto M Saraiva Journal: Trials Date: 2012-12-27 Impact factor: 2.279